Generic Name: Choriogonadotropin Alfa
ATC Class: G03GA08
VA Class: HS900
Chemical Name: Gonadotropin, chorionic (human α-subunit protein moiety reduced), complex with chorionic gonadotropin (human β-subunit protein moiety reduced)
Molecular Formula: C437H682N122O134S13
CAS Number: 177073-44-8
Gonad-stimulating hormone; biosynthetic (recombinant DNA-derived) form of human chorionic gonadotropin (hCG).1
Uses for Ovidrel
Used in conjunction with other infertility agents (e.g., gonadotropin-releasing hormone agonist, FSH) for induction of final follicular maturation and early luteinization in ovulatory, infertile women during assisted reproductive technology (ART) programs.1 2 3 6 7 8 9
Use in patients with tubal obstruction only if participating in ART programs.1
Ovidrel Dosage and Administration
Prior to treatment initiation with choriogonadotropin alfa, perform a thorough gynecologic and endocrinologic evaluation; assess pelvic anatomy and rule out early pregnancy, primary ovarian failure (as indicated by increased serum concentrations of FSH and LH and low serum estrogen concentrations), and neoplasms.1 4 5 6 7 c (See Contraindications under Cautions.) Perform a thorough diagnostic evaluation in patients who demonstrate abnormal uterine bleeding and other signs of endometrial abnormalities.1 4 (See Contraindications under Cautions.) Evaluate partner’s infertility.1 4 5 6 h
When ultrasound assessment and serum estradiol concentrations show sufficient follicular maturation, administer choriogonadotropin alfa 1 day after last dose of follicle-stimulating agent to complete final follicular maturation and induce ovulation.1 4 5
Withhold further follicle-stimulating therapy and delay or withhold choriogonadotropin alfa if ovaries show an excessive response to treatment with gonadotropins because of increased risk of ovarian hyperstimulation syndrome (OHSS).1 4 5 6 i j (See Ovarian Hyperstimulation Syndrome under Cautions.)
Encourage daily sexual intercourse beginning 1 day prior to administration of choriogonadotropin alfa until ovulation occurs (as determined by rise in basal body temperature, increase in serum progesterone concentrations, and menstruation following shift in basal body temperature).l (See Adequate Patient Evaluation and Monitoring under Cautions.)
Maximum 500-mcg single dose studied in clinical trials.f
Cautions for Ovidrel
Risk of mild to moderate uncomplicated ovarian enlargement; may be accompanied by abdominal distention and/or pain, but generally regresses without treatment within 2–3 weeks.1 Careful monitoring of ovarian response recommended.1
If ovaries are abnormally enlarged during controlled ovarian stimulation, withhold choriogonadotropin alfa during current course of therapy to minimize risk of OHSS.1 4 5 6 j (See Ovarian Hyperstimulation Syndrome under Cautions.)
Ovarian Hyperstimulation Syndrome
Risk of potentially severe OHSS, characterized by apparent dramatic increase in vascular permeability that may result in rapid accumulation of fluid in peritoneal cavity, thorax, and potentially, pericardium.1 i j
May progress rapidly (within 24 hours to several days).1 Initial manifestations include severe pelvic pain, nausea, vomiting, and weight gain.1 i Other symptoms include abdominal pain/distention, diarrhea, severe ovarian enlargement, dyspnea, and oliguria.1 j Hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic events may occur.1 i j
Occurs most often after completion of gonadotropin therapy, reaching maximum severity after 7–10 days; usually resolves spontaneously with onset of menses.1 i Monitor patients for ≥2 weeks after hCG administration.1 l OHSS may be more severe and protracted if pregnancy occurs.1 i
Multiple ovulations resulting in multiple gestations reported in 30.9 or 13.3% of women during ART programs or ovulation induction, respectively.1
Potential for arterial thromboembolism exists.1
Fetal/Neonatal Morbidity and Mortality
May cause fetal harm; exclude pregnancy before initiating treatment.d
Animal studies indicate adverse effects on pregnancy outcomes and/or labor.d (See Contraindications under Cautions.)
Adequate Patient Evaluation and Monitoring
Administer only under supervision of qualified clinicians experienced in fertility disorders and interpretation of indices of ovulation.1
Monitor follicular development (e.g., using transvaginal ultrasound, serum estradiol concentrations) to correctly identify follicular maturation, determine timing of choriogonadotropin alfa administration, detect ovarian enlargement, and minimize risks of OHSS and multiple gestation.1 4 5
Obtain clinical confirmation of ovulation from direct and indirect indices of progesterone production, including rise in basal body temperature, an increase in serum progesterone concentrations, and menstruation following shift in basal body temperature.1 2 6 7 Sonographic evidence of ovulation includes findings of fluid in cul-de-sac, ovarian stigmata, collapsed follicle, and secretory endometrium.1
Category X.1 (See Fetal/Neonatal Morbidity and Mortality and also Contraindications under Cautions.)
Safety and efficacy not established.1
Safety and efficacy not established.1
Safety and efficacy not established.1
Safety and efficacy not established.1
Common Adverse Effects
Interactions for Ovidrel
No formal drug interaction studies to date.1
Radioimmunoassays for gonadotropins
Possible cross-reaction with radioimmunoassays for gonadotropins, particularly LH1
Individual laboratories should establish degree of cross-reactivity with their gonadotropin assay1
When requesting gonadotropin concentration determinations, inform laboratory of choriogonadotropin alfa therapy1
Median apparent volume of distribution is 21.4 L in women undergoing in vitro fertilization.1
Excreted in urine principally as metabolites.a
Biphasic; median terminal half-life is 29.2 hours in women undergoing in vitro fertilization.1
Pharmacokinetics not evaluated in patients with renal or hepatic impairment.1
Substitutes for the endogenous LH surge responsible for ovulation and stimulates late maturation of the ovarian follicle, resumption of oocytic meiosis, and initiation of rupture of the preovulatory ovarian follicle.1 2 3 f Spontaneous midcycle LH surges are inconsistent during controlled ovarian stimulation.g
Advice to Patients
Importance of discussing duration of treatment and required monitoring procedures.1
Importance of patients informing clinician if severe pain or bloating in abdominal or pelvic area, severe upset stomach, vomiting, or weight gain occurs.c
Importance of patient informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.c
Importance of women informing their clinician if they plan to breast-feed.c
Importance of informing patient of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Injection, for subcutaneous use only
257.5 mcg/0.515 mL (delivers 250 mcg)
Ovidrel (available as a 0.515-mL, disposable prefilled syringe)
AHFS DI Essentials. © Copyright, 2016, American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
Date published: June 01, 2008
Last reviewed: June 01, 2008
Date modified: February 08, 2016
1. Serono Inc. Ovidrel (choriogonadotropin alfa) injection prescribing information. Randolph, MA; 2004 Jan.
2. European Recombinant Human Chorionic Gonadotropin Study Group. Induction of final follicular maturation and early luteinization in women undergoing induction for assisted reproduction treatment—recombinant HCG versus urinary HCG. Hum Reprod. 2000; 15:1446-51. [PubMed 10875887]
3. Driscoll GL, Tyler JP, Hanagan JT et al. A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod. 2000; 15:1305-10. [PubMed 10831560]
4. Serono Laboratories Inc. Gonal-F (follitropin alfa) for injection prescribing information. Randolph, MA; 1997 Sep.
5. Organon. Follistim (follitropin beta) for injection prescribing information. West Orange, NJ; 1997 Sep.
6. Practice Committee, American Society of Reproductive Medicine. Induction of ovarian follicle development and ovulation with exogenous gonadotropins. A technical bulletin. Birmingham, AL; 1998. From ASRM website.
7. Institute for Clinical Systems Improvement. Diagnosis and management of infertility. Bloomington, MN; 2000 July. From the ICSI website.
8. Yoshida TM. Infertility update: use of assisted reproductive technology. J Am Pharm Assoc. 1999; 39:65-72.
9. Serono Inc: Personal communication.
a. Norman RJ, Buchholz MM, Somogyi AA et al. hCGβ core fragment is a metabolite of hCG: evidence from infusion of recombinant hCG. J Endocrinol. 2000; 164:299-305. [PubMed 10694369]
b. Trinchard-Lugan I, Khan A, Porchet HC et al. Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotropin in healthy male and female volunteers. Reprod Biomed Online. 2002; 4:106-15.
c. EMD Serono. Ovidrel (choriogonadotropin alfa) prefilled syringe FAQ’s. Rockland, MA; 2007. Available from website. Accessed 2007 Nov 27.
d. Serono Inc. Ovidrel (choriogonadotropin alfa) injection prescribing information. Rockland MA; 2006 Jul.
e. Beckers NGM, Macklon NS, Eijkemans MJ et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab. 2003; 88:4186-92. [PubMed 12970285]
f. Chan CCW, Ng EHY, Tang OS et al. A prospective, randomized, double-blind study to compare two doses of recombinant human chorionic gonadotropin in inducing final oocyte maturity and the hormonal profile during the luteal phase. J Clin Endocrinol Metab. 2005; 90:3933-8. [PubMed 15870129]
g. European Recombinant LH Study Group. Recombinant human leuteinizing hormone is as effective as, but safer than, urinary human choriogonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab. 2001; 86:2607-18. [PubMed 11397861]
h. International Recombinant Human Chorionic Gonadotropin Study Group. Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rHCG) and urinary HCG. Fertil Steril. 2001; 75:1111-8. [PubMed 11384635]
i. Practice Committee, American Society of Reproductive Medicine. Ovarian hyperstimulation syndrome. An educational bulletin. Fertil Steril. 2006; 86:S178-83. [PubMed 17055817]
j. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002; 8:559-77. [PubMed 12498425]
k. Stenman U, Tiitinen A, Alfthan H et al. The classification, functions and clinical use of different isoforms of HCG. Hum Reprod Update. 2006; 12:769-84. [PubMed 16877746]
l. EMD Serono Laboratories Inc. Gonal-F (follitropin alfa) for injection prescribing information. Randolph, MA; 2005 Aug.
m. AHFS drug information 2007. McEvoy GK, ed. Choriogonadotropin Alfa. Bethesda, MD: American Society of Health-System Pharmacists; 2007:3115-6.